Showing results (111-120 of 293) with videos related to
Sort By:
Pageof 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Irinotecan plus temozolomide for relapsed or refractory neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2009
Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.Cancer|January 8, 2005
Five-day courses of irinotecan as palliative therapy for patients with neuroblastomaBrian H Kushner, Kim Kramer, Shakeel Modak, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 23, 2024
A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate CancerNeeta Pandit-Taskar, Joseph A O'Donoghue, Dushen Chetty, et al.Pediatric Blood & Cancer|November 5, 2010
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecanBrian H Kushner, Kim Kramer, Shakeel Modak, et al.Gynecologic Oncology|January 11, 2011
Sentinel lymph node biopsy in the management of early-stage cervical carcinomaJohn P Diaz, Mary L Gemignani, Neeta Pandit-Taskar, et al.Hybridoma and Hybridomics|September 27, 2003
Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapyNai-Kong V Cheung, Hong-Fen Guo, Shakeel Modak, et al.International Journal of Cancer|December 18, 2023
GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastomaJaume Mora, Shakeel Modak, Joyce Kinsey, et al.Hybridoma and Hybridomics|February 8, 2003
Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteinsNai-Kong V Cheung, Hong-Fen Guo, Shakeel Modak, et al.NPJ Precision Oncology|February 13, 2026
Complete remission of relapsed ATXN2L::JAK2 fusion positive anaplastic large cell lymphoma following ruxolitinib monotherapy in a childTal Cohen, Ting Zhou, Ukuemi Edema, et al.Pageof 30